Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Age
22 - No limit years
Sex
ALL
Healthy Volunteers
No
Arizona Advanced Eye Research Institute
Glendale, Arizona, United States
Start Date
October 13, 2023
Primary Completion Date
January 31, 2025
Completion Date
November 1, 2027
Last Updated
August 22, 2025
201
ACTUAL participants
Bimatoprost Implant System (High Dose)
DRUG
Bimatoprost Implant System (Low Dose)
DRUG
Timolol Maleate Ophthalmic Solution, 0.5%
DRUG
Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
DEVICE
SpyGlass IOL
DEVICE
Lead Sponsor
SpyGlass Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441